ReviewWorld journal of gastroenterology2016
How to predict clinical relapse in inflammatory bowel disease patients.
Review in World journal of gastroenterology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 83 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
83 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Disclosing Inflammatory Bowel Disease: A Systematic Review and Meta-Synthesis Exploring the Experience of, and Barriers and Facilitators to, Self-Disclosure.Journal of clinical psychology in medical settings · 2025Pooled it
- Peer support for carers and patients with inflammatory bowel disease: a systematic review.Systematic reviews · 2022Pooled it
- Vitamin D Supplementation and Mental Health in Inflammatory Bowel Diseases and Irritable Bowel Syndrome Patients: A Systematic Review.Nutrients · 2021Pooled it
- Evidence for a Modulatory Effect of a 12-Week Pomegranate Juice Intervention on the Transcriptional Response in Inflammatory Bowel Disease Patients Reducing Fecal Calprotectin Levels: Findings From a Proof-of-Principle Study.Molecular nutrition & food research · 2025Trial
- Association of Biomarker Cutoffs and Endoscopic Outcomes in Crohn's Disease: A Post Hoc Analysis From the CALM Study.Inflammatory bowel diseases · 2020Trial
- Relapse Prevention by Plant-Based Diet Incorporated into Induction Therapy for Ulcerative Colitis: A Single-Group Trial.The Permanente journal · 2019Trial
- Beyond Inflammation: Sarcopenia and Disease Phenotype Predict Unfavourable Course in Crohn's Disease-A Retrospective Observational Study.Biomedicines · 2026Article
- Therapy Persistence and Dose Escalation of Advanced Treatments in First and Second Line of Ulcerative Colitis and Crohn's Disease - A Retrospective Cohort Analysis of Healthcare Claims Data.Zeitschrift fur Gastroenterologie · 2026Article
- Long-term regulatory effects of high-fiber low-fat diet on gut microbiota diversity and inflammatory marker expression in DSS-induced recurrent colitis in mice.Open medicine (Warsaw, Poland) · 2026Article
- Interplay between volemic balance and the intestinal tract: insights on biomarkers and diagnostic tests used to assess intestinal morphofunctional barrier.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas · 2026Review
- Inflammatory Bowel Disease Outcomes in Northern Iran: A Retrospective Cohort Study of Remission, Complications, and Treatment Strategies.BioMed research international · 2026Article
- Performance of Novel Inflammatory Bowel Disease-Specific Models for Risk Adjustment.Risk management and healthcare policy · 2026Article
- Real-world patterns of inflammatory bowel disease treatment across adult and pediatric populations: a nationwide cohort study in South Korea.Frontiers in medicine · 2026Article
- Combined metabolomic and metagenomic analysis reveals inflammatory bowel disease diversity in pediatric and adult patients.World journal of gastroenterology · 2025Article
- Neutrophil-mediated degradation of type III collagen is elevated in inflammatory bowel disease and DSS-induced colitis reflecting early mucosal damage.Scientific reports · 2025Article
- (-)-Fenchone Ameliorates TNBS-Induced Colitis in Rats via Antioxidant, Immunomodulatory, and Cytoprotective Mechanisms.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Predictive biomarkers for anti-TNF alpha therapy in IBD patients.Journal of translational medicine · 2024Review
- Histologic features and predicting prognosis in ulcerative colitis patients with mild endoscopic activity.The Korean journal of internal medicine · 2024Article
- Article
- Hydrogen gas and the gut microbiota are potential biomarkers for the development of experimental colitis in mice.Gut microbiome (Cambridge, England) · 2024Article
23 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inflammatory bowel diseases have a natural course characterized by alternating periods of remission and relapse. Disease flares occur in a random way and are currently unpredictable for the most part. Predictors of benign or unfavourable clinical course are required to facilitate treatment decisions and to avoid overtreatment. The present article provides a literature review of the current evidence on the main clinical, genetic, endoscopic, histologic, serologic and fecal markers to predict aggressiveness of inflammatory bowel disease and discuss their prognostic role, both in Crohn's disease and ulcerative colitis. No single marker seems to be reliable alone as a flare predictor, even in light of promising evidence regarding the role of fecal markers, in particular fecal calprotectin, which has reported good results recently. In order to improve our daily clinical practice, validated prognostic scores should be elaborated, integrating clinical and biological markers of prognosis. Finally, we propose an algorithm considering clinical history and biological markers to intercept patients with high risk of clinical relapse.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.